Yixintang Pharmaceutical Group Co., Ltd.
SZSE:002727.SZ
21.31 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 17,301.379 | 17,431.616 | 14,587.401 | 12,656.284 | 10,479.093 | 9,176.27 | 7,751.139 | 6,249.336 | 5,321.152 | 4,428.41 | 3,546.662 | 2,842.14 | 2,218.508 | 1,850.166 | 1,455.978 |
| Cost of Revenue
| 11,750.346 | 11,322.298 | 9,196.52 | 8,122.961 | 6,424.132 | 5,457.027 | 4,532.526 | 3,669.398 | 3,090.299 | 2,637.763 | 2,142.457 | 1,757.965 | 1,355.913 | 1,159.918 | 924.977 |
| Gross Profit
| 5,551.033 | 6,109.318 | 5,390.882 | 4,533.323 | 4,054.961 | 3,719.243 | 3,218.614 | 2,579.938 | 2,230.853 | 1,790.647 | 1,404.205 | 1,084.174 | 862.595 | 690.248 | 531.001 |
| Gross Profit Ratio
| 0.321 | 0.35 | 0.37 | 0.358 | 0.387 | 0.405 | 0.415 | 0.413 | 0.419 | 0.404 | 0.396 | 0.381 | 0.389 | 0.373 | 0.365 |
| Reseach & Development Expenses
| 10.204 | 8.744 | 5.39 | 0.839 | 0.239 | 0.146 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 75.475 | 67.067 | 64.61 | 68.663 | 72.445 | 55.409 | 49.647 | 56.107 | 60.216 | 47.74 | 29.741 | 42.93 | 35.032 | 104.235 | 77.441 |
| Selling & Marketing Expenses
| 4,234.675 | 4,071.861 | 3,700.705 | 3,051.801 | 2,834.268 | 2,454.574 | 2,157.168 | 1,750.539 | 1,475.613 | 1,123.711 | 919.223 | 693.711 | 551.897 | 444.653 | 327.981 |
| SG&A
| 4,600.711 | 4,138.928 | 3,765.315 | 3,120.464 | 2,906.712 | 2,509.983 | 2,206.815 | 1,806.646 | 1,535.829 | 1,171.451 | 948.964 | 736.641 | 586.929 | 548.888 | 405.421 |
| Other Expenses
| -106.578 | 349.127 | 320.56 | 437.646 | 343.329 | 414.345 | 367.831 | 18.452 | 12.836 | 2.375 | 6.419 | 6.335 | 2.029 | 2.384 | -4.539 |
| Operating Expenses
| 4,717.493 | 4,496.8 | 4,091.266 | 3,558.949 | 3,250.28 | 2,924.474 | 2,574.646 | 2,110.113 | 1,791.632 | 1,386.735 | 1,117.645 | 867.411 | 694.52 | 559.779 | 414.467 |
| Operating Income
| 833.539 | 1,661.881 | 1,067.942 | 917.928 | 739.219 | 684.329 | 687.382 | 392.578 | 379.015 | 344.427 | 264.343 | 198.888 | 156.325 | 123.946 | 109.78 |
| Operating Income Ratio
| 0.048 | 0.095 | 0.073 | 0.073 | 0.071 | 0.075 | 0.089 | 0.063 | 0.071 | 0.078 | 0.075 | 0.07 | 0.07 | 0.067 | 0.075 |
| Total Other Income Expenses Net
| -123.636 | -426.903 | 28.58 | 38.964 | 9.831 | 7.346 | -140.524 | -60.444 | -49.093 | -58.569 | -16.612 | -11.942 | -10.172 | -4.611 | -11.769 |
| Income Before Tax
| 709.903 | 1,234.978 | 1,096.523 | 956.893 | 749.05 | 691.675 | 546.858 | 409.381 | 390.127 | 345.343 | 269.949 | 204.821 | 157.903 | 125.858 | 104.765 |
| Income Before Tax Ratio
| 0.041 | 0.071 | 0.075 | 0.076 | 0.071 | 0.075 | 0.071 | 0.066 | 0.073 | 0.078 | 0.076 | 0.072 | 0.071 | 0.068 | 0.072 |
| Income Tax Expense
| 142.151 | 222 | 179.316 | 167.727 | 145.732 | 171.9 | 124.112 | 55.814 | 43.689 | 50.298 | 30.589 | 22.852 | 25.141 | 24.411 | 20.003 |
| Net Income
| 549.442 | 1,009.996 | 921.584 | 789.96 | 603.918 | 521.07 | 422.714 | 353.377 | 346.439 | 297.309 | 240.853 | 182.551 | 134.71 | 102.945 | 84.849 |
| Net Income Ratio
| 0.032 | 0.058 | 0.063 | 0.062 | 0.058 | 0.057 | 0.055 | 0.057 | 0.065 | 0.067 | 0.068 | 0.064 | 0.061 | 0.056 | 0.058 |
| EPS
| 0.92 | 1.7 | 1.56 | 1.38 | 1.06 | 0.92 | 0.81 | 0.68 | 0.67 | 0.65 | 0.62 | 0.47 | 0.35 | 0.28 | 0.24 |
| EPS Diluted
| 0.92 | 1.7 | 1.56 | 1.38 | 1.06 | 0.92 | 0.81 | 0.68 | 0.67 | 0.65 | 0.62 | 0.47 | 0.35 | 0.28 | 0.24 |
| EBITDA
| 2,165.948 | 2,662.521 | 2,465.594 | 1,147.724 | 924.15 | 906.74 | 760.267 | 562.496 | 520.081 | 448.48 | 321.146 | 247.555 | 190.827 | 132.686 | 118.248 |
| EBITDA Ratio
| 0.125 | 0.153 | 0.169 | 0.091 | 0.088 | 0.099 | 0.098 | 0.09 | 0.098 | 0.101 | 0.091 | 0.087 | 0.086 | 0.072 | 0.081 |